Contact Us
Please Contact Us

toll free: 1800 3070 6727    Email Id: info@positivebioscience.com

cancer

Cancer Patients

PositiveSelect is available for all Cancers.

cancer

Breast cancer

  Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in females in India, accounting for 1,50,000 cases in 2015 as per Globocan. Traditionally, treatment decisions have been based on tumor histology and the status of the below three biomarkers:

  • ER (estrogen receptor 1, or ESR1)

  • PR (progesterone receptor, or PGR)

  • HER2 (erb-b2 receptor tyrosine kinase 2, or ERBB2, also known as neu)

  In breast cancer, genomics has made a significant progress and there are good genomics test which can help you fight your cancer better.

  After breast cancer surgery you can avoid unnecessary chemotherapy with Endopredict, a 12 gene breast cancer recurrence test while the PositvieSelect test can help you choose best treatment.

  Apart from the three routinely tested biomarkers ER,PR and HER2 other biomarkers like AR expression, PI3K/AKT1/MTOR pathway, FGFR1, FGFR2, CCND1, CDK4, RB1, TP53, PTEN mutations also play a significant role in development and progression of breast cancer.

  Depending on stage of breast cancer various genomics test can help you fight your cancer.

Depending on stage of Breast cancer various genomics test can help you fight your cancer.

  • endopredict

    Breast cancer recurrence test for ER+ve, HER2 negative patients post surgery

    Patients can avoid unnecessary chemotherapy after surgery

    12 gene test done in Myriad Genetics laboratory, Germany

  • Cancer

    Helps in determining the best treatment option by analyzing all relevant genetic changes

    Improve survival, reduce treatment side effects and decrease treatment cost with this test

    India's best-selling cancer genomics test

  • brac_analysis

    Must to do test for all breast cancer patients to know the hereditary association of breast cancer

    BRCA testing determines the risk of secondary cancer in contra-lateral breast and ovarian cancer

    Predictive and prognostic utility to treat breast cancer

overian

Ovarian Cancer

  Ovarian cancer is one of the most common cause of cancer death in India, with an estimated 26,800 new cases and 20,000 deaths estimated for 2016 (Globocan 2016).

  Most ovarian cancer patients get diagnosed in very advanced stages

  Genomics tests can allow for personalized diagnostic, predictive, prognostic, and therapeutic strategies as;

  • 10–20% of high grade ovarian cancers are associated with germline mutations in BRCA1/2.

  • Somatic alterations in BRCA1/2 and other genes associated with DNA repair are seen in approximately 50% of high grade ovarian cancers

  • BRCA positive patients respond better to DNA damaging agents cisplatin and PARP inhibitors like Olaparib

  Type of ovarian cancer determines which gene is more involved in driving the cancer.BRAF and KRAS mutations are common in Type I tumors which are slow growing and confined to the ovary, and are less sensitive to standard chemotherapy.

Frequent genetic alterations in Ovarian Cancer
Gene BRCA BRAF KRAS PIK3CA PTEN TP53
Ovarian Cancer 10-20% 11% 11% 6.7% 20% Upto 90%

Depending on the stage of ovarian cancer various genomics test can help you fight your cancer.

  • brac_analysis

    Must do test for all ovarian cancer patients to know the hereditary association of cancer

    BRCA positive cases responds better to cisplatin

    Predictive and prognostic utility

  • Cancer

    Helps in determining the best treatment option by analyzing all relevant genetic changes

    Improve survival, reduce treatment side effects and decrease treatment cost with this test

    India's best-selling cancer genomics test

  • brac_cdx

    Only USFDA approved companion diagnostic test for PARP inhibitor Olaparib

    Patients coming positive on BRACAnalysisCDX can benefit with PARP inhibitor therapy

    Done in tumour and detects 50% more mutations thus benefiting more patients

colorical

Colorectal Cancer

  Colorectal cancer is one of the leading cause of cancer deaths in India, with an estimated 64,000 new cases and 48,000 deaths anticipated in 2016 (Globocan 2016 ).

  Survival in metastatic colorectal cancer has more than doubled in last two decades due to advent of more chemotherapy options and with the availability of newer biologics.

  The main histologic subtype of colorectal cancer is adenocarcinoma. Colorectal adenocarcinomas arise through the acquisition of a series of mutations that occur over the space of many years, and results in the evolution of normal epithelium to adenoma to carcinoma to metastasis.

  In the past two decades, there has been increasing recognition that some somatic mutations may be prognostic or predictive markers for specific therapies available in colorectal cancer.

  These mutations involve genes such as KRAS, BRAF, PIK3CA, AKT1, SMAD4, PTEN, NRAS, BRCA1, BRCA2 and TGFBR2

  Furthermore, there has been increasing recognition that some of these mutant gene products may be targets for drug development.

Depending on sthe tage of colorectal cancer various genomics test can help you fight your cancer.

  • positive_select

    Helps in determining the best treatment option by analyzing all relevant genetic changes

    Improve survival, reduce treatment side effects and decrease treatment cost with this test

    India's best-selling cancer genomics test

  • colaris

    Must do test for all colorectal cancer patients to know the hereditary association of cancer

    COLARIS is a test for Lynch syndrome and tests disease-causing mutations in the MLH1, MSH2, MSH6, PMS2, EPCAM and MYH genes and also MYH-associated polyposis (MAP) cases.

    Predictive and prognostic utility

  • myrisk

    Determines hereditary risk to Prostate Cancer

    Checks for all genes strongly associated with Prostate Cancer

    Predictive and prognostic utility

LungCancer

Lung Cancer

  Lung cancer is the leading cause of cancer related deaths in India, with an estimated 70,000 new cases and 63,000 deaths anticipated in 2016 (Globocan 2016 ).

  Genomics testing is a must in lung cancer as it is normally detected in stage 3 when survival chances are less than between 5 to 14%.

  Genomics testing can improve survival chances many fold by getting you on the right treatment.

  • E.g. HER2 biomarker is not tested routinely. It is present in 2% to 4% lung cancers. Patients with HER2 over-expression can benefit immensely from Herceptin.

  • Like HER2 there are many genes associated with lung cancer. It is important to test all to get to the right treatment option.

  If you have NSCLC (non-small cell lung cancer) then you must check for the following genes to know your optimum treatment option

  Altered genes include FGFR1 and DDR2 as well as PIK3CA can also direct treatment in lung cancer.

  Mutations are found in all NSCLC histologies (including adenocarcinoma, squamous cell carcinoma (SCC), and large cell carcinoma).

key

Drugs approved in NSCLC.

Drugs approved in NSCLC but for other molecular subtype.

Drugs approved in other cancer.

Drugs in clinical development.

Gene AKT1 ALK BRAF DDR2 EGFR FGFR1 HER2 KRAS MEK1 METa NRAS PIK3CA PTEN RET ROS1 a
Alteretion Mutation Rearrangement Mutation Mutation Mutation Amplification Mutation Mutation Mutation Amplification Mutation Mutation Mutation Rearrangement Rearrangement
Frequency in NSCLC 1% 3–7% 1–3% ~4% 10–35% 20% 2–4% 15–25% 1% 2–4% 1% 1–3% 4–8% 1% 1%

Depending on stage of Lung cancer various genomics test can help you fight your cancer.

  • positive_select

    Helps in determining the best treatment option by analyzing all relevant genetic changes

    Improve survival, reduce treatment side effects and decrease treatment cost with this test

    India's best-selling cancer genomics test

  • protect_onco

    Must do test to know the genetic risk of cancer

    It tests for top 10 most prevalent cancer including lung cancer

    Predictive and prognostic utility

  • protect_health

    Ideal for people with family history of cancer.

    Identifies risk to 1000+ disease and recommends customised prevention plan

    Reduce your risk by following nutrigenomics and lifestyle modification

prostate

Prostate cancer

  Prostate cancer is a common disease that affects men, usually in middle age or later. In this disorder, certain cells in the prostate become abnormal and multiply without control or order to form a tumor.

  About 1 in 7 men will be diagnosed with prostate cancer at some time during their life.

  Most men who are diagnosed with prostate cancer do not die from it; but it still is the leading cause of cancer death among men in India.

  On diagnosis of prostate cancer genomics test is a must to identify the following:

  • Aggressiveness of cancer: Most common treatment for prostate cancer is prostatectomy. Prostatectomy helps save life of only 1 person out of every 16 patients who undergo the process but more than half patients will experience severe side effects like urinary incontinence, sexual dysfunction etc.. Genomics test can help identify patients who needs prostatectomy and save patients from this complicated surgery.

  • Metastatic Prostate Cancer: Genomics test will help to determines the best treatment option.

Depending on stage of Lung cancer various genomics test can help you fight your cancer.

  • positive_select

    Helps in determining the best treatment option by analyzing all relevant genetic changes

    Improve survival, reduce treatment side effects and decrease treatment cost with this test

    India's best-selling cancer genomics test

  • polaris

    Determines aggressiveness of Prostate Cancer

    Ideal for newly diagnosed patient to determine they need the surgery or not

    Predictive and prognostic utility

  • myrisk

    Determines hereditary risk to Prostate Cancer

    Ideal for newly diagnosed patient to determine they need the surgery or not

    Predictive and prognostic utility

Copyright ©2017 Positive Bioscience, Inc. All Rights Reserved